Scarica l'app Stockscreener
3.02
0.66%
-0.02
Dopo l'orario di chiusura:
3.02
Precedente Chiudi:
$3.04
Aprire:
$3.02
Volume 24 ore:
215.73K
Relative Volume:
0.63
Capitalizzazione di mercato:
$208.34M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-9.7419
EPS:
-0.31
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
-1.95%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+88.75%
Intervallo 1D:
$2.86
$3.05
Intervallo di 1 settimana:
$2.86
$3.15
Portata 52W:
$0.97
$4.00
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics to Report Third Quarter 2024 Financial Result - GuruFocus.com
Trevi Therapeutics (TRVI) Set to Announce Earnings on Wednesday - MarketBeat
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - StreetInsider.com
Trevi Therapeutics Adds Clinical Development Expertise in Chroni - GuruFocus.com
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. - Yahoo Finance
Trevi Therapeutics shares retain buy rating on Haduvio prospects By Investing.com - Investing.com UK
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright - MarketBeat
Trevi Therapeutics completes enrollment for Phase 2a trial - Investing.com
Trevi Therapeutics completes enrollment for Phase 2a trial By Investing.com - Investing.com Australia
Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio - Marketscreener.com
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - Citizentribune
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Citizentribune
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: - GuruFocus.com
Oppenheimer maintains Outperform on Trevi Therapeutics on Haduvio potential By Investing.com - Investing.com Canada
Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley - MarketBeat
Trevi Therapeutics reports progress in clinical trials - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Trevi updates on clinical progress for chronic cough treatment - The Pharma Letter
Trevi Therapeutics reports progress in clinical trials By Investing.com - Investing.com UK
Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com
Trevi Therapeutics hits 50% enrollment in IPF cough study By Investing.com - Investing.com South Africa
Trevi Therapeutics hits 50% enrollment in IPF cough study - Investing.com India
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - Kilgore News Herald
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer - The Malaysian Reserve
President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 - StockTitan
Logos Global Management LP Purchases 600,000 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Financial Health Report: Trevi Therapeutics Inc (TRVI)’s Ratios Tell a Tale - The Dwinnex
Ally Bridge Group NY LLC Invests $4.40 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Taking the lead: Trevi Therapeutics Inc (TRVI) - SETE News
Trevi Therapeutics (TRVI) 10K Form and SEC Filings 2024 - MarketBeat
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Portage Biotech (PRTG): Wild Ride Continues, But Uncertainty Looms - BP Journal
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
UChicago Medicine Patient First in the World to Re | Newswise - Newswise
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval - UChicago Medicine
Traws Pharma, Inc. Announces Special Shareholders Meeting Results - StockTitan
Taking a Closer Look At Trevi Therapeutics Inc (TRVI) Following Its Recent Trade - Knox Daily
trivago (NASDAQ:TRVG) Sees Large Growth in Short Interest - Defense World
FDA Approves Tremfya for Ulcerative Colitis - Physician's Weekly
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow
trivago (NASDAQ:TRVG) Short Interest Up 16.9% in August - MarketBeat
Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat
Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Trevi Therapeutics Inc Azioni (TRVI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Option Exercise |
1.43 |
1,840 |
2,631 |
215,153 |
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Sale |
3.03 |
4,219 |
12,784 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Sale |
3.04 |
1,840 |
5,587 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Option Exercise |
1.43 |
40,277 |
57,596 |
253,590 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Option Exercise |
1.43 |
10,981 |
15,703 |
224,294 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Option Exercise |
1.43 |
3,863 |
5,524 |
217,176 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Sale |
3.11 |
40,277 |
125,310 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Sale |
3.02 |
10,981 |
33,205 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Sale |
3.02 |
3,863 |
11,677 |
213,313 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):